In cell viability dose–response assays, IDH1mut glioma cells were much more sensitive to an FDA-approved pan-HDACi, panobinostat, compared to their IDH1/2wt counterparts, with a 4.1 fold difference in IC50 values (Fig. 2a, b; Fig. S3; Table S2). This evidence concerns the gene IDH1 and central nervous system cancer.